ZULRESSO access and patient support.

Not an actual patient.

Not an actual patient.

ZULRESSO REMS

ZULRESSO REMS1

ZULRESSO is available only through a restricted program under a REMS called the ZULRESSO REMS because excessive sedation or sudden loss of consciousness can result in serious harm.

Notable requirements of the ZULRESSO REMS include the following1:

Healthcare facilities

Healthcare facilities must enroll in the program and ensure that ZULRESSO is only administered to patients who are enrolled in the ZULRESSO REMS.

Icon of a hospital

Patients

Patients must be enrolled in the ZULRESSO REMS prior to administration of ZULRESSO.

Icon of a patient

Pharmacies

Pharmacies must be certified with the program and must only dispense ZULRESSO to healthcare facilities who are certified in the ZULRESSO REMS.

Icon of a medicine bottle

Wholesalers and distributors

Wholesalers and distributors must be registered with the program and must only distribute to certified healthcare facilities and pharmacies.

Icon of a clipboard

Further information is available at:

or

Sage Central Patient Support

Support starts here: A personalized support program offering a range of resources for your patients with PPD

Sage Central offers the following resources and support for your patients:

Live support

Dedicated Sage Central Navigators help patients throughout the treatment journey

Icon of a headset

Logistical support

Assistance in finding options for a ZULRESSO REMS-certified Healthcare Setting

Icon of five arrows pointed outwards symmetrically surrounding a circle

Financial assistance

  • Helping patients understand their insurance coverage and options
  • Providing financial assistance programs for eligible patients
Icon of a calculator

Additional resources

  • Educational resources and helpful treatment preparation tips
  • Assistance with connecting your patients to potential sources of support within their communities
Icon of a laptop

Financial assistance programs

Sage Central logo

Sage Central Financial Assistance Programs

We understand that paying for treatment can sometimes be challenging. That's why Sage Central has financial assistance programs to help patients reduce their out-of-pocket costs related to their treatment. Once patients are enrolled in Sage Central, they will be automatically enrolled in the financial assistance programs for which they may be eligible. A patient's continued eligibility is subject to their satisfaction of the terms and conditions of the financial assistance programs.

The ZULRESSO Drug Copay Assistance Program

The program is designed to help reduce a patient's eligible out-of-pocket copay costs related to the drug. Subject to certain terms and conditions, commercially insured patients may be eligible for copay assistance to reduce their out-of-pocket, drug-related copay costs up to $15,000—regardless of income level.*

The ZULRESSO Infusion Copay Assistance Program

The program is designed to help reduce a patient's eligible out-of-pocket copay costs related to the infusion. Subject to certain terms and conditions, commercially insured patients may be eligible for copay assistance to reduce their out-of-pocket, infusion-related copay costs up to $2,000—regardless of income level.

(Residents of Michigan, Minnesota, Massachusetts, and Rhode Island are not eligible for infusion assistance.)

Free Drug Program

Provides ZULRESSO at no cost for eligible patients who would not otherwise have access to ZULRESSO and who meet certain income criteria. If your patient is uninsured or underinsured and meets our financial eligibility criteria, she may qualify for the Free Drug Program. Subject to terms and conditions and eligibility criteria.

The healthcare setting will be required to provide an attestation that it will not bill the patient or the patient's insurer for any costs associated with ZULRESSO.

*ZULRESSO DRUG COPAY ASSISTANCE PROGRAM TERMS AND CONDITIONS

The ZULRESSO Drug Copay Assistance Program (the “Drug Copay Program”) helps eligible patients with private, commercial health insurance pay for a patient's out-of-pocket costs associated with the drug up to a maximum of $15,000. Cash paying patients and patients eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program. or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud"), are not eligible to participate in the Drug Copay Program. Sage Therapeutics, Inc. may rescind, revoke or amend the Drug Copay Program at any time. For full patient eligibility requirements and program terms and conditions, visit SageCentralSupport.com.


ZULRESSO INFUSION COPAY ASSISTANCE PROGRAM TERMS AND CONDITIONS

The ZULRESSO Infusion Copay Assistance Program (the "Infusion Copay Program") helps eligible patients with private. commercial health insurance pay for a patient's out-of-pocket, infusion-related costs associated with ZULRESSO up to a maximum of $2,000. Cash paying patients and patients eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid. TRICARE, Veteran Affairs health care, a state prescription drug assistance program. or the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud"), are not eligible to participate in the Infusion Copay Program. Residents of Massachusetts, Michigan, Minnesota and Rhode Island are not eligible to participate in the Infusion Copay Program. Sage Therapeutics. Inc. may rescind, revoke or amend the Infusion Copay Program at any time. For full patient eligibility requirements and program terms and conditions, visit SageCentralSupport.com.


FREE DRUG PROGRAM TERMS AND CONDITIONS

To be eligible to participate in the ZULRESSO'" Free Drug Program (the "FOP"), the patient must: (i) Be prescribed ZULRESSO tor an on-label diagnosis; (ii) Have household income less than or equal to 500% of the Federal Poverty Level (FPL); (iii) Be uninsured or rendered uninsured under any of the following circumstances: (a) Patient has no healthcare insurance, (b) Patient is insured but such insurance does not cover ZULRESSO, or (c) Patient is insured with coverage for ZULRESSO, but is ineligible for the ZULRESSO Copay Assistance Programs, and cannot afford the medication (patient out-of-pocket costs are greater than $25}; (iv) Reside in the United States or a U.S. territory: (v) Be treated by a healthcare professional in the United States or a U.S. territory; and (vi) Be 18 years of age or older. Patients enrolled in Medicare, Medicaid or any other federal or state funded health plan may participate in the FOP if they receive the free product outside of their government-funded benefits. The treating healthcare provider must certify that based on his/her independent medical judgment, ZULRESSO is a medically appropriate treatment tor the patient. The healthcare provider must agree not to bill the patient or the patient's insurer for any costs associated with ZULRESSO and the corresponding treatment, including costs associated with the infusion of ZULRESSO (administration, needles, tubing. infusion bags, syringes, infusion pump, preparation of medication, and IV access) and hospital room and board costs. The healthcare provider must certify that he/she will not seek reimbursement from any third-party payer or government program tor the cost of ZULRESSO or any costs associated with the infusion of ZULRESSO. The patient will be informed that she must not (i) seek reimbursement tor the free drug from their health plan, and (ii) count the cost of the free drug towards her out-of-pocket spending requirements, if any, under her insurance. The free drug provided under the FOP is not conditioned on any past or future purchases. For any patient enrolled in a readily identifiable Medicare. Medicaid or other government funded plan, Sage will send a letter to the plan informing it that: (i) the patient is receiving free product from the ZULRESSO FOP outside of the patient's Medicare/Medicaid plan benefit, (ii) the patient and her physician have been informed that they must not seek reimbursement for the free drug from their health plan or count the cost of the free product towards the patient's out-of-pocket spending requirements, and (iii) the plan should discontinue any pending prior authorization or coverage appeal associated with the patient.